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Objective: Stroke places a huge burden on society in terms
of premature death, disability, and costs of care. Increas-
ingly, the cost-effectiveness of new interventions needs to
be demonstrated before their widespread implementation.
Clinical trials are unable to measure the long-term impact
of such new interventions in stroke care, and a modeling
approach is necessary. The Stroke Outcome Model has
been developed in four countries: France, Germany, the
United Kingdom, and the United States as a ﬂexible tool
for this purpose.
Method: The decision-analytic model represents the man-
agement of acute stroke and long-term care and preven-
tion of recurrence for stroke survivors. The latter consists
of semi-Markov state-transition processes, with health
states deﬁned by therapy, disability, and occurrence of
further stroke. Sources of clinical data include trials,
meta-analyses, and prospective cohort studies such as 
the Oxfordshire Community Stroke Project and the
Northern Manhattan Stroke Study. Resource use data
were obtained from published sources and expert clini-
cian panels. Outcome measures used were strokes
averted, life years, and quality-adjusted life-years gained.
Results: The model has been used to undertake economic
analyses of antiplatelet therapy for the prevention of
recurrent strokes, and of stroke unit care and throm-
bolytic therapy in acute stroke. From a health- and social-
care perspective, new interventions were found to be cost
saving or to provide health beneﬁts at modest additional
cost. Results were sensitive to the cost perspective, time
horizon, baseline risk of stroke recurrence, and choice of
effectiveness measure.
Conclusion: The development of this model highlights 
the need for improved information on prognosis and
resources used by stroke survivors and the importance of
differentiating between economically distinct end points
such as death, disabled survival and nondisabled survival,
which may be combined as outcomes in clinical trials.
Keywords: cerebral ischemia, cerebrovascular disease,
cost-effectiveness analysis, costs and cost analysis, deci-
sion analysis, modeling, platelet aggregation inhibitors,
stroke units, thrombolytic therapy.
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ABSTRACT
Introduction
The Need for a Modeling Approach
The social and economic consequences of stroke
place a considerable burden on society in terms of
premature death, long-term disability, restricted
social functioning, and costs of care. In the United
States alone there are over 500,000 new stroke
events each year, of which over 150,000 result in
death and a further 150,000 lead to moderate or
severe permanent disability of the sufferer [1,2].
The combination of an aging population, declining
stroke case-fatality rates, and limited reductions in
the incidence of stroke has resulted in an increase
in the prevalence of stroke survivors [3].
Cost-of-illness analyses in England and Wales,
Scotland, and the Netherlands have reported that
stroke alone accounts for 3% to 4% of the direct
costs of health care [4–6]. In 1993 it was estimated
that the direct medical cost attributable to stroke 
in the United States was $17 billion, or 2% of US
health-care expenditure [1]. This estimate has since
been updated to $30 billion [7]. These costs may be
matched by the cost to society of reduced produc-
tivity of stroke sufferers due to premature mortal-
ity, temporary morbidity, or long-term disability.
This cost was estimated to be $13 billion in the
United States in 1993, updated to $16 billion in
1999 [7].
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Between 10% and 30% of stroke survivors enter
institutional care [8–10], where they may remain
for many years. A further group of survivors
requires supported or sheltered accommodation,
and many of those with moderate or severe dis-
ability who return home require a full-time care-
giver. This places a burden on government or
private funders of social care as well as a ﬁnancial
burden on stroke sufferers and other family
members, who may forgo other employment oppor-
tunities to care for disabled stroke survivors [11].
Effective interventions in stroke treatment and
prevention affect not only levels of mortality or
functional status in the short term, but also levels
of disability, quality of life, and cost consequences
for stroke survivors and their care-givers over the
medium-to-long term. Clinical trials are limited in
their ability to deliver appropriate information for
economic evaluations in stroke care and prevention
because of their relatively short duration, strict in-
clusion and exclusion criteria, varied treatment pat-
terns in different countries, and treatment patterns
that are not representative of nontrial centers.
Health outcome measurement in stroke trials has
been focused on somewhat crude measures such as
survival and global disability. The measurement of
quality of life among stroke survivors with poten-
tially multiple cognitive and physical impairments
is problematic [12]. Few trials have reported the
impact of stroke on other family members.
A model-based approach, which synthesizes data
from trials and other sources, is therefore unavoid-
able. Models are necessary to estimate the long-
term cost impact and consequences of interventions
as well as the impact on the economic results of
varying assumptions about risks of events, effec-
tiveness of therapy, the cost of the intervention
itself, and patient care. Recently reported studies
using a modeling approach to evaluate interven-
tions in stroke care and prevention in the United
States [13–16] have either addressed particular
health-care issues or have used complex and expen-
sive methods and data sources. We have not found
model-based cost-effectiveness studies of stroke
care or prevention in European countries.
This paper reports the concepts and development
of the Stroke Outcome Model (SOM), which pro-
vides a ﬂexible and comprehensive tool for evaluat-
ing the short- and long-term outcomes and costs 
of preventive and acute treatment strategies in
countries with different clinical practices and 
organization of stroke care. Four models have 
been developed in France, Germany, the United
Kingdom, and the United States. These have been
used to conduct economic evaluations of
antiplatelet therapies for prevention of recurrent
stroke and stroke unit care and thrombolytic
therapy for acute stroke.
Method
The design of the SOM consists of a generic
modular structure (Fig. 1), including a semi-
Markov process with predeﬁned inception cohorts,
cycle lengths, health states, health outcomes and
costs, and transition events and probabilities
[17,18]. The generic structure and parameter deﬁn-
itions were reviewed by external clinical experts and
models were developed for each study country.
Adaptations of the model representing prevention
of recurrent stroke (only) were made for Canada
and Spain.
The models were developed using conventional
decision-analytic software (DATA TreeAge Version
3.5, 1998). MS ® Excel (Excel97, 1997) was used
to calculate parameter values for the DATA models
and presentation of model-based results.
Standard sources [MEDLINE, EMBASE] were
used to search for information on effectiveness of
interventions, event risks for stroke, other vascular
events or death, and costs of stroke care in each
country. Relevant journals were hand searched for
pertinent studies dating back to the early 1990s.
Unpublished reports and other “gray literature”
relating to speciﬁc treatment patterns and resource
use in each country were also consulted.
Effectiveness data for key interventions were
obtained from published trial results, analyses
undertaken by the project sponsor, and meta-
analyses of the antiplatelet and stroke unit trials
[19,20]. Information about event risks among
patients following an initial stroke was obtained
through collaboration with the Northern 
Manhattan Stroke Study [21], and data from the
Oxfordshire Community Stroke Project were also
obtained [22,23]. Because sufﬁciently comprehen-
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Figure 1 Schematic overview of Stroke Outcome Model.
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sive data from most countries were unavailable,
with the exception of the cost of acute care and
rehabilitation in the United States, it was necessary
to convene panels of expert physicians and thera-
pists who provided estimates of the resources used
by stroke patients. A modiﬁed Delphi process was
used to elicit the views of panel members. A ﬁnal
report containing an amended summary of their
responses was then prepared and circulated among
panel members for validation.
An advisory board of independent clinicians 
and health economists was convened to review the
model development and results obtained from early
analyses. Further peer review of the model was also
sought at conference presentations of the model
structure and clinical assumptions [24,25] and by
publication of the results of model-based analyses
[26].
Description of the Model
The Stroke Outcome Model consists of two
modules: acute care and long-term care/prevention
of recurrence among stroke survivors. A prototype
primary prevention module has also been devel-
oped. The structure is presented in Figure 1 and the
main elements of each module are listed in Table 1.
The model has been constructed so that results from
the long-term care/prevention of recurrence module
may be used as payoffs in the acute care module.
Thus, both long-term consequences of acute events
and interventions during acute care may be 
considered.
Long-term care and prevention of recurrence
module. Figure 2 describes the long-term care
module. Long-term care and prevention of stroke
recurrence are represented as a conventional semi-
Markov process. Thirty-day survivors of an initial
(ischemic) stroke are allocated to model health
states according to their disability status and the
choice of ﬁrst-line therapy to prevent stroke
recurrence. Over successive cycles patients may die,
suffer further strokes or other vascular events, or
they may withdraw from therapy. The probability
of these events may vary with time from the initial
stroke. Withdrawal from therapy may be associated
with potentially costly adverse events, and some of
these patients may be switched to second-line
antiplatelet therapy (not shown). Following a
recurrent stroke, previously nondisabled survivors
may become disabled. The model also allows for
patients to become disabled over time for reasons
unrelated to a subsequent stroke, although these
probabilities have not been estimated. Nonfatal
vascular events and therapy options after a
subsequent stroke are not considered explicitly.
This module can be used to estimate the number
of recurrent events, time on therapy, life years, 
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Figure 2 Long-term care/prevention of recurrence module.
Table 1 Module components
Component Acute care Long-term care and prevention of recurrence
Inception cohort Ischemic stroke sufferer, presenting within three to six hours of onset 30-day survivors of (ischemic) stroke, aged 70
Type of model Decision tree Markov process
Cycle length Not applicable 3 months
Time horizon 30 days/3 months Lifetime (25 years)
Health states Not applicable Combinations of:
Disabled/not disabled
Therapy (sec prev): on/off
Recurrent stroke
Dead
Health outcomes Mortality (3 months) Recurrent strokes
Disability (3 months) Life years
Intracranial hemorrhage Stroke-free life years
Disability-free life years
Quality-adjusted life years
Disability status Disabled: modiﬁed Rankin 3–5 Disabled: modiﬁed Rankin 3–5
Not disabled: modiﬁed Rankin 0–2 Not disabled: modiﬁed Rankin 0–2
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life years free of disability, and life years free of
recurrent stroke. Costs and health outcomes have
been converted to present values using recom-
mended discount rates for each country.
In France, Germany, and the United Kingdom the
cost of care has been estimated by applying repre-
sentative schedules of unit costs to panel-based esti-
mates of resources required to manage patients. In
the United States it has been possible to draw from
published analyses that report such costs. Unit costs
were adjusted to the base year (1996–1997) using
country-speciﬁc inﬂation indices [27].
Four categories of resource use have been 
distinguished:
1. Acute care includes stabilization, general
patient management in hospital, mobilization,
and rehabilitation before discharge from hospi-
tal. It also includes outpatient follow-up after
discharge attributable to the stroke event, or in
some cases outpatient management of stroke
sufferers who are not admitted;
2. Active rehabilitation is deﬁned as a planned
package of therapeutic interventions following
a stroke event frequently initiated during the
acute hospital stay and continued after hospi-
tal discharge. This is aimed at maximizing func-
tional recovery and is usually completed within
6 months;
3. Long-term care includes the cost of institutional
care, “maintenance” rehabilitation (regular but
relatively infrequent check-ups with therapists),
and of medical care such as regular check-ups
with clinicians and therapists aimed at review-
ing and maintaining functional status;
4. Therapy-related resource use is that associated
with the use of preventive medications, any
associated adverse events, and withdrawal from
therapy. 
Long-term care costs and therapy costs are associ-
ated with Markov health states, and acute care and
rehabilitation costs with transition events occurring
to patients. Differentiation of the cost of acute 
care and rehabilitation depends on availability of
data.
A broad health and social service perspective 
has been used to estimate resource use and costs for
each country model. Supplementary analyses have
focused on a narrower health insurance perspective.
Indirect costs (forgone economic productivity due
to premature mortality or temporary or permanent
inability to work) were not included in the models.
Personal care costs and the cost of informal family
care have not generally been included, except that
the latter has been estimated indirectly in Germany
through use of ofﬁcial rates for disability beneﬁts.
With the exception of the United States, where pub-
lished cost estimates have been used, the cost 
of long-term medical care after stroke has not been
included because this is unlikely to be attributable
to the stroke itself.
Time horizons of 2, 5, and 25 years have been
used for model-based analyses. Two years corre-
sponds to the duration of many secondary stroke
prevention trials from which effectiveness para-
meters have been drawn. Five years corresponds to
the duration of many prospective cohort studies
that may provide event rates and may correspond
to the planning horizons used by clinicians and 
policymakers. Analyses based on the projected life-
time of stroke-survivors (25 years) provide results
that are more readily comparable with those from
other economic evaluations.
Three studies in the United States have associated
utilities with the disability status of stroke survivors
[28–30]. We have estimated the utility of being in 
a disabled or nondisabled state following a stroke
by applying these values to reported distributions 
of stroke survivors by modiﬁed Rankin score
[8,22,31]. The resulting values have been used to
develop estimates of quality-adjusted life years and
associated cost-utility analyses.
Acute care module. The ﬁrst 90 days of acute
management of stroke are represented by a
conventional decision tree. The cohort of stroke
patients hospitalized alive is allocated to a
particular therapeutic strategy of interest. Figure 3
represents the choice of thrombolytic therapy with
or without a further neuroprotective agent. An
alternative tree (not shown) has been developed for
stroke unit versus conventional care [20].
Immediate events occurring during the index
hospital stay may include symptomatic intracranial
hemorrhage (SICH), systemic bleed, other adverse
events or death from another cause, usually vascu-
lar. Subsequent events up to 90 days are classiﬁed
as recurrent ischemic strokes (fatal or nonfatal),
other fatal or nonfatal vascular events, or death
from another cause. It is assumed that a maximum
of one “immediate” event and one “subsequent”
event may occur to any cohort member.
Finally, survivors at 90 days are classiﬁed as
being disabled or not disabled, and as receiving sec-
ondary prevention therapy or not. When integrated
with long-term care, the tree (Fig. 3) becomes the
ﬁrst cycle of the semi-Markov state-transition
process.
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The model also allows for a distinction to be
made between mild and severe strokes as measured
by the National Institutes of Health (NIH) stroke
scale. These are likely to generate different costs for
acute care as well as different health outcomes, and
event rates may be affected by interventions of
interest.
Model Parameters and Information Sources 
Stroke recurrence. Baseline (i.e., no therapy)
probabilities of recurrent stroke over the ﬁrst 2
years were based on an analysis of patients entering
the placebo arm of the second European Stroke
Prevention Study (ESPS-2) with a qualifying event
of stroke only (Table 2). ESPS-2 compared low-
dose aspirin, modiﬁed-release dipyridamole, the
coformulation, and placebo in prevention of stroke
recurrence and other vascular events over 2 years 
in 6602 patients with qualifying transient ischemic
attack (TIA) or stroke [32,33]. In European
countries the results of the Oxfordshire Community
Stroke Project (OCSP) were used to obtain rates 
of recurrent stroke over 3 to 5 years. The OCSP was
a prospective cohort study that reported 5-year
survival, recurrence, and disability following 625
ischemic strokes occurring in Oxfordshire in
1981–85 [22,23]. Age-speciﬁc rates of recurrence
from OCSP (excluding strokes occurring within the
NPA: Neuroprotective agent; SICH: Symptomatic Intracranial Haemorrhage;
IS: Ischaemic Stroke; VE: Vascular Event (including MI);
SB: Systemic Bleed; AE: Adverse Event; DIS: Disabled (Rankin 3-5);
NDIS: Not Disabled (Rankin 0-2);
ON: On secondary prevention therapy; OFF: Off secondary prevention therapy
no tPA
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Figure 3 Acute care module.
Table 2 Prevention of recurrence: event probabilities (percent)
Parameter France Germany UK US Source
Recurrent stroke (baseline rate for each 3-month cycle)
Months 1–3 4.9 4.9 4.9 4.9 Years 1–2 (all countries): ESPS-2 placebo group, patient with qualifying
Months 4–12 2.1 2.1 2.1 2.1 stroke only [32]
Months 7–10 2.0 2.0 2.0 2.0
Months 11–12 2.0 2.0 2.0 2.0
Year 2 after stroke 1.5 1.5 1.5 1.5
Years 3–5 after stroke 1.3 1.3 1.3 1.5
Years 6–15 after stroke 1.8 1.8 1.8 1.5
Years 16+ after stroke 2.5 2.5 2.5 1.5
Other events (baseline rate for each 3-month cycle)
Other vascular events (mostly MI) 1.2 declining to 0.5 Years 1–2 (all countries): ESPS-2 placebo group (with qualifying stroke
Transient ischaemic attack 2.7 declining to 1.4 only); years 3+: rate projected from ESPS-2 rate for year 2 [32]
Mortality, excluding acute stroke (rate per 3-month cycle)
Months 1–3 5.4 5.4 5.4 5.3 Years 1–5 (France, Germany, UK): OCSP [22,23]
Months 4–12 3.2 3.2 3.2 4.3 Years 6+ (France): OCSP rate ratios applied to INSERM [37]
Months 7–10 2.3 2.3 2.3 3.3 Years 6+ (Germany): OCSP rate ratios applied to StBA [38]
Months 11–12 2.0 2.0 2.0 2.4 Years 6+ (UK): OCSP rate ratios applied to OPCS [39]
Year 2 after stroke 1.5 1.5 1.5 1.9 Years 1–5 (US): NOMASS [21]
Years 3–5 after stroke 1.5 1.5 1.5 1.9 Years 6+ (US): OCSP rate ratios applied to CDC [40]
Years 6–15 after stroke 3.0 3.5 3.6 1.9
Years 16+ after stroke 5.3 4.8 4.5 3.8
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ﬁrst year) were used to project rates of recurrence
for subsequent years (6 or more) after the index
stroke. Rates per 3-month period declined from
4.9% in the ﬁrst 3 months to 1.5% in the second
year and further to 1.3% in subsequent years before
a projected rise as the cohort aged.
In the United States rates were projected beyond
2 years based on an analysis of the Northern 
Manhattan Stroke Study (NOMASS). NOMASS is
a prospective cohort study that examines risk
factors for recurrent stroke and other events among
a community-deﬁned cohort of survivors of
ischemic stroke in the northern Manhattan area
[21]. At the time of model construction, 3-year
follow-up was complete for over 800 patients.
Rates of stroke recurrence reported for the
NOMASS trial patients (1.5% per 3-month period
in the long term) are lower than those reported in
earlier studies [34–36]. The impact of using differ-
ent baseline rates of recurrent stroke was tested in
sensitivity analysis.
Rates of other vascular events (mostly myo-
cardial infarction) and TIA were calculated from
ESPS-2 (placebo group, qualifying stroke), and the
rate for the second year was projected indeﬁnitely.
Mortality. Case fatality rates attributed to recurrent
strokes alone were based on the results of ESPS-2
(Table 3) [32]. Rates varied from 14.8% (placebo
group) to 20.4% (dipyridamole alone). Comparable
case fatality rates for ticlopidine and clopidogrel
were calculated based on the assumption that
overall mortality was the same as that for aspirin.
Rates of cohort mortality for survivors at 3
months after an initial stroke were based on data
from NOMASS and OCSP (Table 2) [21–23]. The
excess mortality among stroke survivors compared
with the general population declines with age, with
little or no excess mortality at ages over 85 [23].
The mortality rate for stroke survivors in Europe at
5 or more years after the index event was extrapo-
lated by multiplying national age-speciﬁc mortality
rates [37–39] by the ratio of the age-speciﬁc mor-
tality rates reported in the OCSP cohort to the 
corresponding age-speciﬁc rates for the general
Oxfordshire population [22]. The US NOMASS
mortality rate for years 2 to 3 after the index event
was extrapolated up to age 85, after which the
general US age-speciﬁc mortality rate was used [40].
Effectiveness. Effectiveness values were derived
from recent trials and meta-analyses of relevant
types of therapy (Tables 3 and 4). Relative risk
reductions for prevention of stroke recurrence from
trials (ESPS-2, TASS, CAPRIE) [32,33,41,42] and
meta-analyses [19,43] were used. Where possible,
different risk reductions were used for different
outcome events: recurrent stroke, other vascular
events, and TIA. For the analysis of thrombolytic
therapy, rates of mortality at 90 days, symptomatic
Table 3 Prevention of recurrence: Effectiveness and withdrawal from therapy (percent)
Therapy
Parameter ASA-DP ASA DP none TIC* CLOP* Sources
Effectiveness (prevention of recurrence) relative risk reduction compared with placebo
Recurrent stroke 39.96 18.08 16.29 0.00 33.9 22.9 ESPS-2 [32] (ASA-DP,ASA, DP vs. placebo), also
Other vascular event 35.90 24.42 20.06 0.00 29.7 31.9 meta-analyses [19,43]
Transient ischemic attack 56.50 31.78 12.69 0.00 31.0 19.6 TASS [41] (TIC vs.ASA)
CAPRIE [42] (CLOP vs. ASA)
Case fatality of recurrent stroke 19.75 17.48 20.38 14.80 22.13 18.98 ESPS-2 [32] (ASA-DP,ASA, DP, PLACEBO)
Assume same overall mortality (i.e. higher case
fatality) for TIC, CLOP as for ASA.
Withdrawal from therapy (rate for each three-month cycle)
Months 1–3 17.5 8.4 16.8 9.5 12.6 7.5 ESPS-2 [32] (ASA-DP,ASA, DP, placebo)
Months 4–12 3.0 4.2 3.6 2.8 6.3 3.7 TASS [41] (TIC: assume rate 50% > ASA)
Months 7–10 2.3 2.8 1.9 2.5 4.2 2.5 CAPRIE [42] (CLOP: assume rate 11% < ASA)
Months 11–12 2.0 1.5 1.9 1.5 2.3 1.3
Months 13–15 1.8 1.8 1.8 1.6 2.7 1.6
Months 16–18 0.8 1.5 1.6 1.5 2.3 1.3
Months 19–21 1.3 1.0 1.5 1.8 1.5 0.9
Months 22–24 1.0 1.8 1.1 1.6 2.7 1.6
After second year 1.2 1.5 1.5 1.6 2.3 1.3
*Based on combining trial results (TASS, CAPRIE) vs. ASA with RRR for ASA vs. placebo from ESPS-2: trial results were TASS (TIC vs. ASA) 21.0% for stroke/
transient ischemic attack and 12.0% for myocardial infarction; CAPRIE (CLOP vs. ASA) 7.9% for stroke/transient ischemic attack and 14.8% for myocardial 
infarction.
Abbreviations: ASA, aspirin (low-dose); ASA-DP, combination of modiﬁed-release dipyridamole and aspirin; CLOP, clopidogrel; DP, modiﬁed-release dipyridamole;
NA, not available;TIC, ticlopidine.
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intracranial hemorrhage (SICH) and other bleeding
events were obtained from a pooled analysis of
recent trials (Table 4: NINDS; ECASS; ECASS-2)
[44–46]. Published rates were adjusted to give
model probabilities of mortality for patients with
and without SICH. Rates of mortality after stroke
at one year for stroke unit and “conventional” care
obtained from a report of the Stroke Unit Trailists
Collaboration were used for analyses of stroke unit
care [20]. Subsequent model probabilities were
adjusted to allow for the longer duration
represented by the “acute care” decision tree.
Disability. Clinician panels conﬁrmed that the
modiﬁed Rankin scale [31] is an appropriate and
valid classiﬁcation of global disability for use in this
model [47]. It is simple and frequently used in trials
and cohort studies, and has been used in other
modeling studies of stroke [14,16]. It was assumed
that most recovery of function after a stroke is
complete at 6 months, and we have deﬁned
“disabled” as modiﬁed Rankin 3 to 5 and “not
disabled” as modiﬁed Rankin 0 to 2. The reliability
of this dichotomous classiﬁcation has not been
tested rigorously, but it was considered to be
adequate for analysis of the OCSP (Dr. J. Burn,
Poole General Hospital, UK, personal commu-
nication). Based on the results of ESPS-2 it was
estimated that 31% of survivors of an initial
ischemic stroke are disabled at 6 months, and that
a further 36% of those remaining nondisabled
become disabled as a result of a subsequent stroke
(Table 4).
The OCSP reported that 36% of survivors of a
ﬁrst cerebral infarction were disabled at 6 months
[22]. Of those nondisabled before the stroke and
surviving to 6 months, 30% (132/442) became dis-
abled. The Rochester study reported that 40% of
survivors at 6 months following any type of stroke
were disabled [8]. Published data on the probabil-
ity of recurrent events or the effectiveness of therapy
by disability status were unavailable. However, the
model allows for testing of different assumptions
about differential mortality of stroke survivors
according to their disability status.
We used trial data to estimate rates of with-
drawal from therapy and therapy-related adverse
events, including bleeding events (Table 3).
Health state valuations. Gage [28] presented
patients’ valuations for health-related quality of life
after stroke on a scale of 0 to 1, in which 1.0 = well,
0.75 = neurological event with mild residua, and
0.39 = neurological event with moderate to severe
residua. These values were adapted to the disability
categories used in the present analysis: 0.85 = not
Table 4 Other probability parameters
Parameter Value (percent) Source
Disability
Survivors (at 3 months) of initial stroke who are disabled 30.9 Derived from ESPS-2 [32]
(mRankin 3–5)
Previously nondisabled (mR 0–2) survivors who become 35.6 Derived from ESPS-2 [32]
disabled (mR3–5) after subsequent stroke
Previously nondisabled (mR 0–2) survivors who become 0 Assumption
disabled (mR3–5) in absence of a subsequent stroke
Health-state valuations
Disabled stroke survivor 0.39 Derived from Gage [28]
Nondisabled stroke survivor 0.85 Derived from Gage [28]
Acute care: thrombolytic therapy within 3 hours TPA no TPA
Symptomatic intracranial hemorrhage 8.8 1.9 Pooled analysis of NINDS [44],
Fatal SICH (given SICH) 45.0 45.0 ECASS [45], ECASS 2 [46]
Death within 90 days, all causes (excluding SICH)* 16.6 21.4
Systemic bleed 1.6 0.0
Other minor bleed 23.0 3.0
Further ischaemic stroke within 3 months 6.8 7.0
Further vascular event within 3 months 1.5 1.5
Disability (mR3–5) of survivors at 3 months 40.2 52.0
Acute care: stroke unit care** Stroke unit care Conventional care
Death at 1 year 23.2 28.7 Stroke unit trialists collaboration [20]
Disability (mR3–5) of survivors at 1 year 48.6 53.2
*Calculated from overall mortality at 90 days: 17.6% (TPA), 18.3% (placebo).
**In this analysis the rates of stroke recurrence/mortality were adjusted to start 1 year after stroke event.
SICH, symptomatic intracranial hemorrhage.
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disabled; 0.39 = disabled. Other studies have
reported very similar differentials in valuations
between disabled and nondisabled survivors [29].
Resource use and costs. Summary cost parameters
included in the long term-care module are presented
in Table 5. Further information on the derivation of
these parameters is provided in the Appendix and
is available from the authors on request.
Length of hospital stay for stroke and other 
conditions and bed-day costs were obtained from
published sources in France [48], Germany [49],
and the United Kingdom [50]. Clinician panels 
estimated the proportion of stroke sufferers who
would be admitted (usually 60–90%) and who
would be readmitted, and any follow-up hospital
outpatient visits required. The costs of ambulatory
rehabilitation were estimated by deﬁning parcels of
different intensity and duration of such care. The
proportion of stroke survivors receiving each parcel
was estimated for each disability category, and 
estimates of the proportion of patients who would
be admitted to a rehabilitation facility and the cost
of a stay in such a facility were added. Long-term
care was separated into maintenance rehabilitation,
referring to check-ups with therapists and doctors,
and the use of different types of residential care by
stroke survivors according to their disability status.
Panel-based estimates of the proportion of stroke
survivors using each service or type of accommo-
dation were combined with appropriate unit costs
available from national sources or a local survey. 
In Germany, model parameters were derived from
a study of stroke survivors in Rheinland-Pfalz 
[51], and costs of long-term care were adjusted to
include beneﬁt payments representing informal
home care.
The cost of acute care for stroke patients in the
United States was obtained from a study of ﬁve aca-
demic medical centers [52], proportions admitted
from Leibson [53], the rates of readmission from
clinician panels, and the cost of readmissions from
Lee [54]. We used results from an authoritative
national analysis of rehabilitation after acute care
for stroke [54] combined with the reports from clin-
ician panels to estimate the cost of ambulatory reha-
bilitation according to disability status, i.e., use of
rehabilitation hospitals, skilled nursing facilities,
and home health. We used published reports of the
proportion of patients discharged to institutional
care facilities [52,53,55], the proportion previously
in institutional care [53], and the excess cost of
ongoing medical care of stroke survivors [56] to
estimate the cost of long-term care.
Prices of drug therapy were obtained from
national sources or directly from the project
sponsor. The costs of treatment-related adverse
events were estimated by applying appropriate unit
costs to treatment patterns for each event described
by clinician panelists and rates obtained from trials.
Results
Table 6 provides illustrative results for model-based
economic evaluations of different therapies or
strategies in stroke care and prevention. All of these
analyses are based on UK treatment patterns and
costs for 1996 and use a broad health- and social-
care perspective, and both costs and health out-
comes are discounted at 6% per annum.
The results of ESPS-2 [32,33] analysis using the
model reported that the combination of low-dose
aspirin and modiﬁed-release dipyridamole com-
pared with aspirin alone generated health gains at
a cost of £2100 per stroke averted and an estimated
£5800 per quality-adjusted life year (QALY) gained
[26]. Over the projected cohort lifetime more favor-
able cost-effectiveness results were obtained, and
these were sensitive to the choice of background
rates of stroke recurrence, effectiveness of therapy,
and the cost of long-term care of disabled stroke
survivors (not shown) [26]. Compared with no
therapy, both therapy options were cost saving.
The model-based analysis has demonstrated that,
Table 5 Model cost parameters: long-term care/prevention of recurrence (1996)
Parameter France (FF) Germany (DM) UK (£) US ($)
Recurrent stroke: acute care 22,000 10,302 2,933 16,200
Transient ischemic attack: acute care 5,300 902 *73 2,300
Other nonfatal vascular event: acute care 26,800 7,000 1,500 11,500
Ambulatory rehabilitation (disabled) 24,300 4,003 718 16,100
Ambulatory rehabilitation (not-disabled) 4,700 192 38 2,500
Long-term care (disabled, 3-months) 16,000 5,308 2,658 7,100
Long-term care (not-disabled, 3-months) 2,300 1,615 206 900
*Values are for all events including those not requiring hospital admission; for example, the low value for transient ischemic attack (TIA) in the UK is based on
the report of a clinician panel, where it was estimated that <10% of TIA patients would be admitted to hospital, and only 30% investigated in an outpatient setting.
Note: See text and Appendix for details of derivation.
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over 5 years, the extra cost of caring for patients
initially treated by stroke unit care rather than 
conventional care was £800 per life year gained, or
£900 per quality-adjusted life year gained [24].
These results assumed that no extra costs were
incurred by the initial stroke unit care itself, but
suggest that even if stroke unit care is more costly
than conventional care, the long-term beneﬁts to
society may be economically justiﬁed.
Results of model-based analysis of rt-PA in acute
ischemic stroke within 3 hours of symptom onset
suggested that in treated patients the savings related
to disability and long-term care considerably out-
weigh any potential extra costs of acute therapy,
given a broad cost perspective and a time horizon
of 2 or more years [25]. The ﬁxed costs of devel-
oping and maintaining a capability to diagnose and
provide early thrombolysis will, however, need to
be taken into consideration in a more comprehen-
sive analysis.
Discussion
Economic Evaluation in Stroke Care
Valuation of the cost of stroke depends on the 
decision-making perspective to be adopted. Sub-
types of stroke such as ischemic stroke, hemor-
rhagic, and subarachnoid hemorrhage differ with
respect to risk factors, age groups affected, out-
comes, and cost of care [52]. Mild strokes may not
be clearly differentiated from transient ischemic
attacks. The distribution of costs is heavily skewed,
with a large proportion of the costs generated by
relatively few individuals [53]. Differences in out-
comes and treatment costs have been reported
between ﬁrst and subsequent stroke events [16].
A large proportion of the cost of stroke falls on
social-care agencies and informal caregivers of dis-
abled stroke survivors. These costs may be borne 
by social insurance in some countries and are not
generally covered by the health-care budget. 
Downstream savings attributed to the prevention 
of social-care costs associated with disability are
unlikely to be very convincing to budget holders
focused on hospital and drug costs alone [57].
Many stroke patients are elderly or have signiﬁ-
cant comorbidity related to atherosclerosis or other
stroke risk factors such as diabetes. Some disability-
related social care and a substantial proportion of
health care received by stroke survivors may not be
attributed directly to the stroke event itself. Recent
studies have attempted to calculate the excess cost
attributable to stroke by subtracting the costs of
age-matched populations [10,53]. In some compar-
ative studies, nonattributable costs may be balanced
between each option and therefore do not con-
tribute to the incremental results. However, the
problem of attribution may not be avoided in
studies of stroke care where certain interventions
such as thrombolysis may reduce mortality, result-
ing in an imbalance of nonattributable costs of
managing unrelated conditions in the surviving
elderly. The issue of whether nonattributable costs
should be included in economic evaluations is under
debate [58].
A review of cost-of-illness studies in stroke has
concluded that the possibility for comparisons
across studies is severely limited by differences in
study methods [59]. Prevalence-based cost-of-illness
Table 6 Illustrative results (cohort of 1000 patients*)
Health outcomes Incremental values
Treatment Costs Life years Strokes QALYs Costs Life years Strokes QALYs
Aspirin-dipyridamole vs. aspirin in prevention of recurrent stroke, in survivors at 30 days of initial stroke) [26]
Aspirin-dipyridamole £14.87m 3,456 151.6 2,410 +£55,200 +2 -27 +10
Aspirin £14.82m 3,454 178.4 2,401
ICER: £27,600 £2,100 £5,800
Stroke unit care vs. conventional care in acute stroke [24]
Stroke unit care £20.59m 3,449 NA 2,144 +£202,000 +247 NA +220
Conventional care £20.39m 3,202 NA 1,924
ICER: £800 £900
Thrombolytic therapy (rt-PA) vs. no early therapy in acute ischemic stroke treated within hours of stroke onset [25]
rt-PA £23.08m 3,036 NA 1,989 -£2,333,000 +25 NA +155
No early acute therapy £25.41m 3,011 NA 1,834
ICER DS DS
*UK health and social care perspective (1996); time horizon 5 years; costs and health outcomes discounted at 6% per annum.
Note: Values may not add precisely due to rounding.
Abbreviations: DS, dominant strategy (cost saving and improved health outcomes); ICER, incremental cost-effectiveness ratio; NA, not applicable; QALY, quality-
adjusted life year.
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studies do not generally give useful information
about the potential of a new intervention to alter
costs or health outcomes. Economic evaluations
require an incidence-based approach in which the
implications of introducing or not introducing the
therapy in terms of health outcomes or costs for a
deﬁned patient group are compared. This requires
a longitudinal view of resources used by stroke sur-
vivors and of health outcomes, including quality 
of life and costs for a cohort of stroke patients or
patients presenting with risk factors for stroke.
Comparisons of costs and health outcomes, such 
as life years or quality-adjusted life years, pro-
jected over a lifetime provide measures of cost-
effectiveness more amenable to comparison with
similar results for competing interventions. Recent
studies have estimated the lifetime cost of stroke in
the Netherlands [6], Sweden [60,61], and United
States [62].
Beneﬁts of a Modeling Approach
Given the limited ability of randomized clinical
trials to provide sufﬁciently comprehensive, gener-
alizable, and long-term information on the resource
use and health consequences of interventions in
stroke care, economic evaluations in this area will
need to rely on modeling techniques. The main
advantage of such an approach is that the estimated
health outcomes and costs most relevant to patients,
clinicians, and policymakers may be compared in a
timely manner. A model provides a ﬂexible tool
with which to study the impact of differences in
prognosis and in cost of care on economic results.
Parameters and results can readily be updated 
when new information becomes available from
meta-analyses of efﬁcacy rather than single trials.
By means of conventional sensitivity analysis, the
impact of modeling assumptions and of particular
parameter estimates can be tested. This may assist
in the planning of future trials or other data-
collection activities. Good practice guidelines for
undertaking and presenting modeling studies have
recently been presented [63,64].
A modeling approach, such as that described
here, synthesizes different types of data from dif-
ferent sources with the aim of maximizing external
validity. This is achieved at the expense of internal
validity to a certain extent. The present model has
used a broad generic structure so that it may be
adapted to different countries, each with different
types of resources used for the care of stroke
patients, and different requirements for economic
evaluation. Although the model is comprehensive in
scope, the modular structure has facilitated its use
for economic evaluations of different interventions
at different stages in the management and preven-
tion of stroke recurrence.
Limitations of the Present Study
Decision models are at best justiﬁable simpliﬁca-
tions of a complex clinical and economic reality.
They are potentially open to criticism concerning
the model structure, the selection and compatibility
of data sources, the calculation of parameter values
(especially when these have been extrapolated 
from source data), and the analytical techniques
employed. It is incumbent on model builders to
clearly describe the model structure and assump-
tions as well as the methods used to derive para-
meter values [65]. However, as the Stroke PORT
investigators have pointed out, rules deﬁning how
much external validation is enough do not exist
[16]. The approach presented here has the follow-
ing limitations.
First, with the partial exception of the United
States, limited published data were found on the
cost of care for stroke survivors in each country. For
this reason we have been dependent on fragmentary
sources and the advice of expert clinician panels.
Many expert panel members found it difﬁcult to
estimate resource use for the long-term social care
of stroke patients, and they were reluctant to con-
sider treatments in areas where they had limited
experience, such as in the case of adverse events
while on thrombolytic therapy. Although it is 
desirable to obtain resource-use data directly from
studies of cohorts of stroke survivors, this informa-
tion is not necessarily generalizable to all treated
populations. Parallel estimates based on a consen-
sus of expert panelists are likely to remain valid,
especially for the estimation of reasonable ranges
for parameter values used in the model [66].
The impact of stroke on indirect costs, informal-
care costs, and on quality of life of other family
members is important. We have excluded these ele-
ments from the model, with the exception of some
estimates of the cost of informal care in Germany.
Indirect costs are attributed to a minority of stroke
sufferers of working age, and there is current theo-
retical debate about how such forgone productivity
should be valued as well as the valuation of non-
wage-earning, home-working activities [67,68].
The use of the modiﬁed Rankin scale [31,69] in
the present model and in others [14,16] to deﬁne
disability after a stroke event and the association of
costs and utilities to Rankin categories requires
further validation. This measure of global disability
is commonly used in trials and other prospective
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studies, with good reported interobserver reliability
[47]. However, the scale was not developed spe-
ciﬁcally for the purpose of utility assessment or 
economic evaluation; it is clinician-assessed and
there are some concerns about its sensitivity [12]. It
is important to be able to differentiate rates of sur-
vival and stroke recurrence for disabled and nondis-
abled survivors after a stroke, as well as the ongoing
proportions of disabled stroke survivors who are 
in institutional care, to accurately estimate the 
long-term consequences of stroke interventions.
However, appropriate data are not available [16].
Many trials of acute interventions report disability
outcomes at 3 months, but some improvement in
function may be expected in patients beyond this
duration.
We have been unable to ﬁnd sufﬁcient published
information on resource use, rates of recurrence, or
disability and mortality by age group to undertake
cost-effectiveness analyses of interventions accord-
ing to important stratifying variables.
Case fatality rates and rates of stroke recurrence
may have declined over recent years. It is possible
that the use of data from prospective cohorts such
as the Oxfordshire Community Stroke Project,
undertaken over 10 years ago, may therefore over-
state the current risk of stroke or stroke recurrence
and associated risk reductions associated with inter-
ventions of current interest.
Finally, the variability of parameter estimates
such as costs of care, resource use, and stroke risks
is not well known, which makes multiway sensitiv-
ity analyses and estimation of conﬁdence-intervals
for economic results based on this model difﬁcult to
achieve.
Conclusion
The Stroke Outcome Model has been developed to
enable the consequences of acute or preventive
therapy for stroke care to be evaluated in four coun-
tries. The model integrates modules representing
acute management and long-term care and preven-
tion of stroke recurrence. We have examined the
cost-effectiveness of antiplatelet therapy in the pre-
vention of stroke recurrence and compared orga-
nized stroke unit care with conventional care and
thrombolytic therapy in early acute stroke. Results
are generally sensitive to the duration of follow-up
and particularly sensitive to the cost perspective
chosen.
Development and use of this model have made
clear the need for improved data on the prognosis
(recurrence, mortality) and costs of caring for
stroke patients, especially in terms of disability
status and, in particular, long-term use of institu-
tional care. It would also be valuable to have more
information about indirect costs and the cost of
informal care attributable to stroke. We require
additional information on the effectiveness of ther-
apies that clearly differentiates between economi-
cally distinct end points of stroke such as death,
disabled survivorship and nondisabled survivor-
ship, and possibly, more information on how
patients and the general public value these different
outcomes of stroke.
The development of models such as the Stroke
Outcome Model is not only desirable but necessary
in assisting clinicians and policymakers to make
informed decisions about the implementation of
new therapies to manage and prevent stroke.
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Appendix
Stroke Outcome Model: Further Details of
Costing Methodology
Derivations of the cost of managing stroke patients
in each study country are provided in Table A1, and
further notes for each country are given below. A
distinction was made between the cost of managing
acute stroke and related cardiovascular events:
“event” costs, and the long-term management of
disabled and non-disabled stroke survivors: “health
state” costs. Rehabilitation in hospital and after dis-
charge was considered an “event” cost associated
with the preceding stroke occurrence and allocated
to the cycle during which the event occurred. In the
model health state costs accrue to patients in rele-
vant Markov states over successive model cycles
until such time as they leave that health state. A
half-cycle correction was used to allow for transi-
tion events occurring mid-way through each three-
monthly cycle. Resource use was estimated as for
1996 and costs adjusted this base year accordingly.
It is likely that certain parameters, such as the
propensity to admit patients with TIA in the UK,
have not remained constant in recent years.
The cost of rehabilitation (outside acute hospi-
tal) and long-term care were estimated separately
for disabled and non-disabled stroke survivors. In
the former case separate estimates was made for res-
idential rehabilitative care and ambulatory rehabil-
itation provided at patient’s own homes or
out-patient clinics. The cost of rehabilitation was
estimated by deﬁning and costing typical “pack-
ages” of different intensity and estimating the 
proportion of disabled and non-disabled patients
receiving each type of package. The need for high
intensity rehabilitation was greatest among moder-
ately disabled patients. Long-term care was com-
posed of separate estimates of the need for
residential care in nursing homes or other supported
accommodation, on-going medical care attributable
to cerebrovascular disease (excluding subsequent
acute events) and long-term “maintenance” reha-
bilitation with therapists.
It was not possible to standardise the approach
to costing across countries, partly because the 
availability of data differed between countries, and
also because clinician panels in each country 
were encouraged to develop their own method of
estimation based on their own knowledge and 
experience.
France
In the absence of published data, estimates are
largely based on clinicians panels, and are therefore
subject to uncertainty. Panels estimated that 80% of
stroke patients would be admitted (for an average
12.4 days [70], of whom 40% would be readmit-
ted as an in-patient or day case, and that 50% of
TIAs would be admitted for 5 days. As in other
countries, there is limited use of outpatient follow-
up. 25% of disabled survivors receive residential
rehabilitation and 23% “high intensity” ambula-
tory rehabilitation. Panel members estimated that
37% of disabled stroke survivors require long-term
residential care (50% in maison de retraite med-
icalisée MRM).
Germany
90% of stroke patients are estimated to be admit-
ted for an average of 20.6 days, of whom 24% are
readmitted. An estimated 25% of TIA patients are
admitted to hospital. 35% of disabled stroke sur-
vivors receive residential rehabilitation, and 10%
“high intensity” ambulatory rehabilitation. Based
on the results from Rheinland-Pfalz [51] 10% of
96 Chambers et al.
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97Decision Model of Stroke Care
disabled stroke survivors were estimated to require
institutional care, and 56% of those at home
require professional care. The clinician panel esti-
mated that 40% of patients require institutional
care, and that 80% of those at home required pro-
fessional care, from which alternative cost estimates
were developed.
United Kingdom
It was estimated that 60% of stroke patients would
be admitted for 30 days, of whom 24% are read-
mitted. Only 6% of TIA patients are estimated to
be admitted, but many would be managed as out-
patients. 38% of disabled survivors require nursing
home care, and a further 57% are in some form of
sheltered housing.
United States
Most US estimates are based on published studies.
83% of stroke patients are estimated to be admit-
ted [53], of whom 30% would be readmitted. An
estimated 40% of TIAs are admitted. Of survivors
with severe disability it was estimated that 20% and
50% respectively would require “high” and “low”
intensity rehabilitation. Corresponding proportions
for moderately disabled survivors were 70% and
20%. It was estimated that 60% of disabled sur-
vivors would require institutional care.
